Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia

NCT07819435 is registered in ClinicalTrials.gov with Pelage Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07819435
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07819435 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind, Vehicle-controlled, Phase 2/3 Study to Assess Efficacy and Long-Term Safety of PP405 in Adult Males With Androgenetic Alopecia
Lead sponsor
Pelage Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
September 21, 2026
Completion date
June 30, 2028
Enrollment
600 (estimated)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

androgenetic alopecia